Home

About Us

About Us
• Company Profile

• Corporate Culture

• Honor

• Development History

• Quality Policy

• Keyuan Pharmaceutical

• Strategic Layout

• ESG report

• Research Institute Introduction

Digital Manufacturing

Digital Manufacturing
• Factory Introduction

• Production Capacity Introduction

• Production Equipment Introduction

• Device detection introduction

• Intelligent Manufacturing Project

Service

Service
• Raw material API CMO/CDMO business

• Pharmaceutical CMO/CDMO business

• Medical beauty material CMO/CDMO business

• Featured pilot platform

Technology

Technology
• Nitration reaction technology

• Hydrogenation reaction technology

• Sulfonation reaction technology

• Fluorination reaction technology

• Chiral catalysis technology

• Enzyme catalysis technology

• Continuous flow technology

• Featured pilot platform

Products

Products
• Active Pharmaceutical Ingredient

• Cosmetics raw materials

• Medical beauty materials

• Food additives

• Pharmaceutical intermediates

News

News
• Keyuan News

• Video

Investor Relations

Investor Relations
• Investor Relations Management System

• Investor Relations Activity Record

• Listing Announcement

Contact Us

Contact Us
The company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
• Leave a message online

• Business hotline

• Join us

中文